I was convicted of that crime of which I am innocent, said Orpis.
Former conservative Senator Jaime Orpis has been bestowed Friday with the dubious honour of becoming Chile s first-ever politician to be handed down a jail sentence for his involvement in acts of corruption.
Orpis, of the ultra-conservative Independent Democratic Union (UDI) party, of the current government coalition of President Sebastián Piñera, was sentenced to five years for the crime of tax fraud and 600 days for bribery, as per a lengthy ruling from the nation s Third Oral Court.
He was found guilty of receiving money in 2013 from the then manager of the company Corpesca - Chile s largest fishing company - in exchange for favouring it during the processing of a new fishing law.
ONTOZRY® (Cenobamate) Receives European Commission Approval for the Treatment of Drug-Resistant Focal-Onset Seizures in Adults apnews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from apnews.com Daily Mail and Mail on Sunday newspapers.
Share this article
PANGYO, GYEONGGI PROVINCE, Korea, Jan. 29, 2021 /PRNewswire/
SK Biopharmaceuticals announced that the European Medicines Agency s (EMA) Committee for Medicinal Products for Human Use (CHMP) has recommended the approval of cenobamate for the adjunctive treatment of focal-onset (partial-onset) seizures with or without secondary generalization in adult patients with epilepsy who have not been adequately controlled despite a history of treatment with at least two anti-seizure medications (ASMs). The European Commission (EC), which is authorized to approve medicines in the European Union, is expected to issue its decision within approximately 67 days of receipt of the CHMP opinion.
SK Biopharmaceuticals and Arvelle Therapeutics entered into a licensing agreement in 2019 for Arvelle to commercialize SK Biopharmaceuticals cenobamate in Europe. Cenobamate has been approved by the U.S. Food and Drug Administration (FDA) for the treatment of partial-onset (focal-ons
ONTOZRY™ (cenobamate) receives positive CHMP opinion for the adjunctive treatment of uncontrolled focal onset seizures in adults
January 29, 2021 12:20 ET | Source: Arvelle Therapeutics Arvelle Therapeutics
Positive CHMP opinion is an important milestone for Arvelle Therapeutics and cenobamate
When approved, cenobamate will provide new hope in helping adult patients with uncontrolled focal epilepsy move closer to the goal of seizure reduction and seizure freedom
ZUG, Switzerland, Jan. 29, 2021 (GLOBE NEWSWIRE) Arvelle Therapeutics, an emerging biopharmaceutical company focused on bringing innovative treatments to patients suffering from central nervous system (CNS) disorders, today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has recommended the approval of cenobamate for the